Otsuka terminates development of treatment for agitation due to Alzheimer’s disease

Otsuka Pharmaceutical has terminated its development of AVP-786, a novel compound that was being researched as a potential treatment for patients with agitation due to Alzheimer’s disease, according to a company-issued press release.

In February, Otsuka announced top-line results from the phase 3 NCT03393520 clinical trial of AVP-786.

Researchers observed no significant difference between AVP-786 and placebo in the primary endpoint of the study, which was average change in the Cohen-Mansfield Agitation Inventory from baseline to week 12, according to the release.

After a detailed analysis of the results from the completed trial, Otsuka said in the release that it decided to terminate the development of AVP-786.